<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12178112</article-id><article-id pub-id-type="pmcid-ver">PMC12178112.1</article-id><article-id pub-id-type="pmcaid">12178112</article-id><article-id pub-id-type="pmcaiid">12178112</article-id><article-id pub-id-type="manuscript-id">NIHMS2084874</article-id><article-id pub-id-type="pmid">40413965</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2025.112679</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2084874</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2084874</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: a retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Howell</surname><given-names initials="BA">Benjamin A.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Black</surname><given-names initials="A">Anne</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="HJ">Hsiu-Ju</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liberatore</surname><given-names initials="MA">Mark A.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Greene</surname><given-names initials="CR">Christina R.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>D&#8217;Onofrio</surname><given-names initials="G">Gail</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heimer</surname><given-names initials="R">Robert</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grau</surname><given-names initials="LE">Lauretta E.</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hawk</surname><given-names initials="K">Kathryn</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fiellin</surname><given-names initials="DA">David A.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Becker</surname><given-names initials="WC">William C.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1 -</label>Section of General Medicine, Yale School of Medicine, New Haven, CT</aff><aff id="A2"><label>2 -</label>Program in Addiction Medicine, Yale School of Medicine, New Haven, CT</aff><aff id="A3"><label>3 -</label>Connecticut Department of Mental Health and Addiction Services, Hartford, CT</aff><aff id="A4"><label>4 -</label>School of Social Work, University of Connecticut, Hartford, CT</aff><aff id="A5"><label>5 -</label>Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD</aff><aff id="A6"><label>6 -</label>Division of Epidemiology (DEPI-II), Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD</aff><aff id="A7"><label>7 -</label>Department of Emergency Medicine, Yale School of Medicine, New Haven, CT</aff><aff id="A8"><label>8 -</label>Yale School of Public Health, New Haven, CT</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> Benjamin A. Howell, MD, MPH, MHS, SEICHE Center for Health and Justice, Yale School of Medicine, 60 Temple St, Suite 5C, New Haven, CT 06510, <email>benjamin.howell@yale.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P42"><bold>Conflict of Interest:</bold> The authors have no financial conflicts of interest to disclose.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>5</month><year>2025</year></pub-date><volume>273</volume><issue-id pub-id-type="pmc-issue-id">491026</issue-id><fpage>112679</fpage><lpage>112679</lpage><pub-history><event event-type="nihms-submitted"><date><day>12</day><month>06</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-20 10:25:38.110"><day>20</day><month>06</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2084874.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background</title><p id="P1">Opioid overdose survivors are at high risk for subsequent overdose. There are few evaluations using real-world data to compare overdose risk after receipt of different addiction treatment modalities.</p></sec><sec id="S2"><title>Objective</title><p id="P2">To assess the association between receipt of different addiction treatment modalities and risk of subsequent opioid overdose among opioid overdose survivors.</p></sec><sec id="S3"><title>Design</title><p id="P3">Survival analysis comparing time-to-subsequent overdose within a cohort of opioid overdose survivors using a linked state-wide individual level data of different addiction treatment modalities: opioid agonists treatments (OAT, i.e., methadone or buprenorphine) and non-medication based inpatient addiction treatments (medically supervised opioid withdrawal and extended inpatient treatment).</p></sec><sec id="S4"><title>Subjects</title><p id="P4">Opioid-involved overdose survivors (N=4,089) admitted to a hospital or emergency department in Connecticut between May 2016 and December 2017</p></sec><sec id="S5"><title>Main Measures</title><p id="P5">Time-to-subsequent overdose (fatal or non-fatal) and time-to-subsequent fatal overdose</p></sec><sec id="S6"><title>Key Results</title><p id="P6">Following the index overdose, 467 (11.4%) experienced another overdose event within 12 months (87 fatal and 380 non-fatal), 35% received OAT (25% buprenorphine and 13% methadone), and 21% received inpatient addiction treatment (19% medically supervised opioid withdrawal and 8% extended inpatient treatment). In survival analyses adjusted for demographics, incarceration, and receipt of non-OAT opioids or benzodiazepines, receipt of methadone (aHR 0.41, 95% CI: 0.26&#8211;0.66) or buprenorphine (aHR 0.72, 95% CI: 0.53&#8211;0.98) was associated with a decreased risk of subsequent overdose compared to no receipt of methadone or buprenorphine, respectively. Neither medically supervised opioid withdrawal (aHR 1.08, 95% CI: 0.77&#8211;1.50) nor extended inpatient treatment (aHR 0.90, 95% CI: 0.53&#8211;1.54) was associated with reduced risk of subsequent overdose. Neither OAT nor non-medication based inpatient treatment modalities were associated with a change in risk of subsequent fatal overdose; benzodiazepine exposure was associated with increased risk (aHR 2.65, 95% CI: 1.66&#8211;4.23).</p></sec><sec id="S7"><title>Conclusion</title><p id="P7">Using statewide data, our findings underscore the importance of OAT to reduce risk of subsequent overdose following a non-fatal opioid overdose.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>